Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Gains from Investment Securities (2020 - 2024)

Lyell Immunopharma's Gains from Investment Securities history spans 5 years, with the latest figure at -$76000.0 for Q4 2024.

  • For Q4 2024, Gains from Investment Securities rose 77.25% year-over-year to -$76000.0; the TTM value through Sep 2024 reached -$258000.0, down 106.05%, while the annual FY2022 figure was $5.0 million, N/A changed from the prior year.
  • Gains from Investment Securities for Q4 2024 was -$76000.0 at Lyell Immunopharma, up from -$12.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $43.6 million in Q3 2021 and bottomed at -$12.9 million in Q2 2024.
  • The 5-year median for Gains from Investment Securities is $1.1 million (2022), against an average of $8.7 million.
  • The largest YoY upside for Gains from Investment Securities was 18742.03% in 2024 against a maximum downside of 25950.0% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $7.0 million in 2020, then surged by 419.93% to $36.4 million in 2021, then plummeted by 89.2% to $3.9 million in 2022, then plummeted by 108.49% to -$334000.0 in 2023, then surged by 77.25% to -$76000.0 in 2024.
  • Per Business Quant, the three most recent readings for LYEL's Gains from Investment Securities are -$76000.0 (Q4 2024), -$12.9 million (Q2 2024), and $13.0 million (Q1 2024).